Whatever happened to Pittsburgh Compound-A?

Alzheimer Disease and Associated Disorders

Volumn 22, Issue 3, 2008, Pages 198-203

  Klunk, William E ^a   Mathis, Chester A ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b PET Facility   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; APOLIPOPROTEIN E; CONGO RED; FLUORINE 18; PITTSBURGH COMPOUND A; PITTSBURGH COMPOUND A C 11; PITTSBURGH COMPOUND B; RADIOPHARMACEUTICAL AGENT; THIOFLAVINE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; BINDING AFFINITY; DRUG APPROVAL; DRUG BINDING; DRUG CLEARANCE; DRUG PENETRATION; DRUG SAFETY; DRUG SYNTHESIS; FOOD AND DRUG ADMINISTRATION; HUMAN; IN VIVO STUDY; ISOTOPE LABELING; MINI MENTAL STATE EXAMINATION; NEUROIMAGING; NEUROPROTECTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; TOXICITY TESTING;

AMYLOIDOSIS; ANILINE COMPOUNDS; ANIMALS; BRAIN DISEASES; FLUORESCENT DYES; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; PORTRAITS AS TOPIC; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; STAINING AND LABELING; THIAZOLES;

EID: 52649120423     PISSN: 08930341     EISSN: None     Source Type: Journal    
DOI: 10.1097/WAD.0b013e318188c0c8     Document Type: Review

References (42)

1. Mathis CA, Wang Y, Klunk WE. Imaging beta-amyloid plaques and neurofibrillary tangles in the aging human brain. Curr Pharm Des. 2004;10:1469-1492.
2. Klunk WE, Debnath ML, Pettegrew JW. Chrysamine-G binding to Alzheimer and control brain: autopsy study of a new amyloid probe. Neurobiol Aging. 1995;16:541-548.
3. Klunk WE, Debnath ML, Koros AM, et al. Chrysamine-G, a lipophilic analogue of Congo red, inhibits A beta-induced toxicity in PC12 cells. Life Sci. 1998;63:1807-1814.
4. Ishii K, Klunk WE, Arawaka S, et al. Chrysamine G and its derivative reduce amyloid beta-induced neurotoxicity in mice. Neurosci Lett. 2002;333:5-8.
5. Styren SD, Hamilton RL, Styren GC, et al. X-34, a fluorescent derivative of Congo red: a novel histochemical stain for Alzheimer's disease pathology. J Histochem Cytochem. 2000;48: 1223-1232.
6. Ikonomovic MD, Abrahamson EE, Isanski BA. et al. X-34 labeling of abnormal protein aggregates during the progression of Alzheimer's disease. Methods Enzymol. 2006:412:123 144.
7. Klunk WE. Bacskai BJ. Mathis CA, et al. Imaging Abeta plaques in living transgenic mice with multiphoton microscopy and methoxy-X04, a systemically administered Congo red derivative. .J Neuro-pathol Exp Neurol. 2002;61:797-805.
8. Sadowski M, Pankiewicz J, Scholtzova H, et al. Targeting prion amyloid deposits in vivo. J Neuropalhol Exp Neural. 2004:63:775 784.
9. Brendza RP, Bacskai BJ, Cirrito JR, et al. Anti-Abeta antibody treatment promotes the rapid recovery of amyloid-associated neuritic dystrophy in PDAPP transgenic mice. .JClin Invest. 2005: 115:428-433.
10. Meyer-Luehmann M, Spires-Jones TL, Prada C, et al. Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer's disease. Nature. 2008;451:720-724.
11. Skovronsky DM, Zhang B, Kung MP, et al. In vivo detection of amyloid plaques in a mouse model of Alzheimer's disease. Proc Natl Acad Sci V S A. 2000;97:7609-7614.
12. Maezawa I. Hong HS, Liu R, et al. Congo red and thioflavin-T analogs detect Abeta oligomers. J Neurochem. 2008;104:457 468.
13. Sato K, Higuchi M, Iwata N, et al. Fluoro-substituted and 13C-labeled styrylbenzene derivatives for detecting brain amyloid plaques. Eur J Med Chem. 2004;39:573-578.
14. Higuchi M. Iwata N, Matsuba Y, et al. I9F and 1H MRI detection of amyloid beta plaques in vivo. Nat Neurosci. 2005;8:527-533.
15. Klunk WE, Wang Y, Huang GF, et al. Uncharged thioflavin-T derivatives bind to amyloid-beta protein with high affinity and readily enter the brain. Life Sci. 2001;69:1471-1484.
16. Mathis CA, Bacskai BJ, Kajdasz ST, et al. A lipophilic thioflavin-T derivative for positron emission tomography (PET) imaging of amyloid in brain. Biorrg Med Chem Lett. 2002;12:295-298.
17. Bergström M, Grahnén A, Långström B. Positron emission tomography microdosing: a new concept with application in tracer and early clinical drug development. Eur J Clin Pharmacol. 2003;59: 357-366.
18. Mills G. The Exploratory IND. J Nucl Med. 2008;49:45N-47N.
19. Mathis CA, Wang Y, Holt DP, et al. Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J Med Chem. 2003;46:2740-2754.
20. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol. 2004;55:306-319.
21. Arnold SE, Hyman BT, Flory J, et al. The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer's disease. Cereh Cortex. 1991; 1:103 116.
22. Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging. 1997;18:351-357.
23. Thal DR, Rub U. Schultz C, et al. Sequence of Abeta-protein deposition in the human medial temporal lobe. J Neuropalhol Exp Neurol. 2000;59:733-748.
24. Helmuth L. Neuroscience. Long-awaited technique spots Alzheimer's toxin. Science. 2002;297:752-753.
25. Bacskai BJ, Frosch MP, Freeman SH, et al. Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report. Arch Neurol. 2007;64:431-434.
26. Ikonomovic MD, Klunk WE, Abrahamson EE, et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain. 2008;131:1630-1645.
27. 11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology. 2006;67:446-452.
28. Pike KE, Savage G. Villemagne VL. et al. β-Amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain. 2007;130:2837-2844.
29. Aizenstein HJ. Nebes RD, Saxton JA, et al. Amyloid deposition is frequent and often is not associated with significant cognitive impairment in the elderly. Arch Neurol. 2008. In press.
30. Forsberg A, Engler H, Almkvist O, et al. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging. 2007;doi:10.1016/j.neurobiolaging.2007.03.029.
31. Kemppainen NM, Aalto S, Wilson IA, et al. PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment. Neurology. 2007;68:1603-1606.
32. Rowe CC, Ng S, Ackermann U, et al. Imaging beta-amyloid burden in aging and dementia. Neurology. 2007;68:1718-1725.
33. Jack CR Jr, Lowe VJ, Senjem ML, et al. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain. 2008; 131: 665-680.
34. Theuns J, Marjaux E, Vandenbulcke M, et al. Alzheimer dementia caused by a novel mutation located in the APP C-terminal intracytosolic fragment. Hum Mutat. 2006;27:888-896.
35. Klunk WE, Price JC, Mathis CA, et al. Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. J Neurosci. 2007;27:6174-6184.
36. 11C-PIB-PET amyloid imaging in patients with APP locus duplication. Arch Neurol. 2008; 65:540-544.
37. 11C]-PIB imaging in patients with Parkinson's disease: preliminary results. Parkinsonism Relat Disord. 2008;14:345-347.
38. 11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration. Neurology. 2007;68:1205-1212.
39. Drzezga A, Grimmer T, Henriksen G, et al. Imaging of amyloid plaques and cerebral glucose metabolism in semantic dementia and Alzheimer's disease. Neuroimage. 2008;39:619-633.
40. 11C]PIB binding in Parkinson's disease dementia. Neuroimage. 2008;39:1027-1033.
41. Johnson KA, Gregas M, Becker JA, et al. Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Ann Neurol. 2007;62:229-234.
42. Neumaier B, Deisenhofer S, Furst D, et al. Radiosynthesis and evaluation of [11C]BTA-1 and [11C]3′-Me-BTA-1 as potential radiotracers for in vivo imaging of beta-amyloid plaques. Nuklear-medizin. 2007;46:271-280.